Stefanie S. Jeffrey

Sarcoma Oncology Center

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index61

i10-index109

Publications246

Citations47,481

Grants

7 total · 0 active

NIH #5R21CA177447-02

A Droplet-Based System for Capture, Manipulation, and Biochemical Profiling of Ra

Amount: $258K
Period: 2013-09-20 → 2016-08-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at STANFORD UNIVERSITY

NIH #1R21CA177447-01

A Droplet-Based System for Capture, Manipulation, and Biochemical Profiling of Ra

Amount: $266K
Period: 2013-09-20 → 2015-08-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at STANFORD UNIVERSITY

NIH #5R01GM085601-04

Epigenetic changes and phenotype-specific therapeutic strategies in breast cancer

Amount: $381K
Period: 2008-08-01 → 2013-07-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 7 of 7

2706P Clinical benefit analysis of a phase I/II study using lurbinectedin combined with ipilimumab and nivolumab as first-line therapy for advanced soft tissue sarcoma (NCT05876715)
Annals of Oncology · 2025-09-01
2702P Clinical benefit analysis of DNG64-CAR-V gene therapy predicts successful efficacy endpoints for a planned phase II basket study for CCNG1 expressing tumors
Annals of Oncology · 2025-09-01
1733P Update on gallant: A phase II study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab in previously treated sarcoma
Annals of Oncology · 2024-09-01 · 1 citations
1771P Blessed: Expanded yccess for DeltaRex-G in vivo gene therapy for sarcoma, pancreas and breast cancer (NCT04091295) and other solid malignancies (IND# 19130)
Annals of Oncology · 2024-09-01
1729P Update on SAINT: A phase II study using trabectedin (T) in combination with ipilimumab (I) and nivolumab (N) in previously treated soft tissue sarcoma
Annals of Oncology · 2024-09-01
1728P Results of TNT: A phase II study using talimogene laherparepvec, nivolumab and trabectedin for advanced leiomyosarcoma and liposarcoma [NCT# 03886311]
Annals of Oncology · 2024-09-01
1739P Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part
Annals of Oncology · 2024-09-01 · 1 citations

Open author page on OpenAlex →